Navigation Links
Active surveillance can reduce suffering among men with prostate cancer
Date:11/2/2012

With active surveillance many men with prostate cancer could dispense with radiation treatment and surgery, and thus avoid adverse effects such as incontinence and impotence. This is the outcome of a study of almost 1,000 men diagnosed with prostate cancer conducted at Sahlgrenska Academy, University of Gothenburg, Sweden.

The introduction of PSA tests, which are used to screen for prostate cancer, offers early tumour detection, reducing mortality rates. At the same time, prostate cancer is in many cases a slow-growing form of cancer. Many men may never develop symptoms during their lifetime, which means that they are being treated unnecessarily and may be forced to live with serious side-effects such as bowel disorders, urinary incontinence and impotence.

In a study involving 968 men, researchers at Sahlgrenska Academy, University of Gothenburg, found that many prostate cancer sufferers could dispense with treatment and avoid side-effects if they instead opted to undergo active surveillance. This study is a substudy within the major prostate cancer screening trial that has been running in Gothenburg since 1995 under the direction of Jonas Hugosson of Sahlgrenska Academy, University of Gothenburg.

"Active surveillance means monitoring development of the tumour through regular PSA-tests and prostate biopsies. If the tumour shows signs of growth or becomes more aggressive, then the next stage is surgery or radiation treatment. Many men can entirely avoid or at any event postpone the adverse effects associated with curative treatment," says Rebecka Arnsrud Godtman, a doctoral student supervised by Jonas Hugosson.

Of the 968 men with prostate cancer studied, around half (46 per cent) opted for active surveillance as the treatment strategy. The majority of the men had low-risk tumours, but there were also men with intermediate or high-risk tumours.

The results show that:

  • Of the 440 men who chose active surveillance, 60 died, but only one death was the result of prostate cancer.
  • None of the men diagnosed with low-risk tumours developed metastatic prostate cancer or died from the cancer.
  • 63 per cent of the men studied continued with active surveillance for the duration of the follow-up period (up to 15 years).
  • 37 per cent of those who chose active surveillance discontinued this in favour of treatment (surgery, radiation treatment or hormone therapy). The main reason was that surveillance revealed that the tumour had grown.
  • Only four men discontinued active surveillance on the grounds that it made them feel anxious.

  • Active surveillance is more risky for men with intermediate or high-risk tumours. The risk to men with intermediate or high-risk tumours of developing incurable and/or terminal cancer was four times greater than that to men with low-risk tumours.

    "Overall, our results show that active surveillance has the potential to reduce overtreatment, enabling more men to avoid side-effects. A large proportion of the tumours detected through PSA screening are low-risk tumours, and older men in particular could dispense with treatment and instead be monitored safely with active surveillance," says Rebecka Arnsrud Godtman.


    '/>"/>

    Contact: Rebecka Arnsrud Godtman
    r.godtman@gmail.com
    46-073-673-7456
    University of Gothenburg
    Source:Eurekalert

    Related medicine news :

    1. Even physically active women sit too much
    2. Attractive names sustain increased vegetable intake in schools
    3. Human genome far more active than thought
    4. Soy Formula May Harm Babies With Underactive Thyroid: Report
    5. Exergames Can Help Inactive Folks Get Moving: Study
    6. When Parents Get Active, So Do Kids: Study
    7. Interactive personal health records increase clinical preventive services
    8. EliNext Completes Development of a Series of Virtual Reality Interactive 5D Simulation Games on Unity 3D
    9. Friends Life Care, a Pennsylvania Based Long-Term Care Provider, Launches VigR eMeetinghouse — An Interactive Online Community
    10. Author, Speaker Richard London Battles Parkinson’s with an Active Lifestyle and the Desire to Give Back
    11. Active, Outdoor Teens Are Happier Teens: Study
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/28/2016)... ... May 28, 2016 , ... SuperCloset is proud to officially launch our ... to day issues, struggles and obstacles veterans’ need to overcome in order to face ... active or retired military veteran(s) with a donated SuperCloset product based on the needs ...
    (Date:5/28/2016)... ... ... After a year and a half of planning the Multiple Pathways of Recovery Conference ... of Recovery Conference was held May 2 -4, 2016 at the Mystic Marriott Hotel ... to explore the many pathways individuals use to get into and sustain their recovery. ...
    (Date:5/27/2016)... ... ... Southland Log Homes , designer and manufacturer of America’s Favorite Log ... be found on its website at SouthlandLogHomes.com. , The designs of the wood ... craftsmanship of timber post and beam construction. The result is a barn that ...
    (Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses and ... to shed lights on the variety of topics detailing why we appreciate nurses in ... why this career has gone from being in a major recession to one of ...
    (Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, ... ... caregivers to casual readers, this installment is bolstered by inspiring human-interest stories, courtesy ... trends and tech within the industry, from leading advocates, associations and industry leaders ...
    Breaking Medicine News(10 mins):
    (Date:5/24/2016)... 24, 2016 ARANZ Medical  Ltd ... healthcare sector, has been named the Coretex Hi-Tech Emerging Company ... Dr Bruce Davey , CEO of ARANZ ...  It,s really good to be recognised for the work we ... are used in 35 countries around the world from Sub-Saharan ...
    (Date:5/24/2016)... 24, 2016 Celsion Corporation (NASDAQ: ... today provided an update on its ongoing OVATION ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... is an IL-12 DNA plasmid vector formulated as ...
    (Date:5/24/2016)... KONG , May 24, 2016 ... , the world , s first ... AV fistula intervention   OrbusNeich, a global ... has expanded its portfolio to include products to treat ... are the company,s first entry devices for lower limb ...
    Breaking Medicine Technology: